Wall Street Zen Downgrades Keros Therapeutics (NASDAQ:KROS) to Strong Sell

Keros Therapeutics (NASDAQ:KROS) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday.

Separately, Wells Fargo & Company reduced their price objective on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Keros Therapeutics presently has a consensus rating of “Hold” and an average target price of $20.40.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $10.50 on Friday. Keros Therapeutics has a 1-year low of $10.30 and a 1-year high of $22.55. The company has a market capitalization of $207.80 million, a P/E ratio of -3.49 and a beta of 0.95. The firm’s 50 day simple moving average is $11.44 and its two-hundred day simple moving average is $15.71.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.19). The firm had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $1.93 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. On average, sell-side analysts anticipate that Keros Therapeutics will post -4.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Keros Therapeutics by 3.3% in the third quarter. Vanguard Group Inc. now owns 2,718,777 shares of the company’s stock worth $43,011,000 after purchasing an additional 87,129 shares during the last quarter. Western Standard LLC increased its position in Keros Therapeutics by 42.7% during the third quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock valued at $34,644,000 after acquiring an additional 654,989 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in Keros Therapeutics by 26.6% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 768,425 shares of the company’s stock valued at $15,645,000 after acquiring an additional 161,336 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Keros Therapeutics by 38.3% during the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after acquiring an additional 205,022 shares during the last quarter. Finally, Federated Hermes Inc. increased its position in Keros Therapeutics by 27.3% during the fourth quarter. Federated Hermes Inc. now owns 654,724 shares of the company’s stock valued at $13,330,000 after acquiring an additional 140,564 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.